Eli Lilly and Co. completed its acquisition of clinical-stage drug developer AtaiBeckley on Sept. 11, bringing the company’s investigational mental-health pipeline inside Lilly Neuroscience and ending AtaiBeckley’s run as an independent public company. The closing converts eligible AtaiBeckley shares into $6.75 in cash per share plus a contingent value right, or CVR, that could deliver as much as another $2.50 per share if specified development, regulatory and drug-rescheduling milestones are met.
The structure gives former shareholders certain cash at closing but leaves more than a quarter of the potential per-share consideration dependent on future outcomes. AtaiBeckley survived the merger as a wholly owned Lilly subsidiary, according to a Sept. 11 AtaiBeckley filing with the Securities and Exchange Commission. The company also told Nasdaq that the merger had closed and requested suspension of trading and delisting of its common stock.
Lilly announced the completion the same day, saying AtaiBeckley would add programs intended for treatment-resistant depression and other mental-health conditions to its neuroscience effort. The acquired portfolio is led by BPL-003, which Lilly describes as an investigational program for treatment-resistant depression. The deal gives Lilly control of a set of assets at a clinical stage where future trial execution and regulatory decisions, rather than a marketed product’s sales, will determine much of their value.
Cash at close, milestones later
The CVR is the transaction’s most consequential financial qualification. Each eligible former AtaiBeckley shareholder receives one right for each share held, with a maximum aggregate payout of $2.50 per right. It is not a second cash payment that was delivered at closing. The filing makes payment contingent on three separate events occurring by fixed deadlines measured from the merger date.
Up to $1 per CVR is tied to initiating a Phase 3 trial for VLS-01 before the fourth anniversary of closing. A further $0.50 depends on both U.S. approval and Drug Enforcement Administration rescheduling of BPL-003 before the fifth anniversary. The final $1 requires U.S. approval and DEA rescheduling of VLS-01 before the seventh anniversary.
Put another way, the stated maximum consideration is $9.25 per share, but only $6.75 was fixed cash consideration at closing. The remaining $2.50 is subject to clinical, Food and Drug Administration and DEA-related conditions. The CVRs cannot be transferred except in limited circumstances, are not exchange-listed and carry neither voting rights nor dividend rights. Those features mean they are not a readily tradeable substitute for the former Nasdaq shares.
The arrangement sets a defined economic timetable around two programs without establishing that either will reach the triggering endpoints. Lilly’s closing announcement itself cautioned that the acquisition might not produce expected benefits or commercially successful products. The SEC terms make the uncertainty more concrete: the biggest portions of the delayed consideration require regulatory approval and DEA action, neither of which has occurred.
What Lilly acquired—and what remains unproven
AtaiBeckley develops so-called neuroplastogens, compounds the company and Lilly are pursuing for mental-health conditions. Lilly has said it sees the approach as potentially supporting rapid-acting therapies and moving away from chronic dosing for some patients. That is a corporate view of the programs’ potential, not clinical proof of efficacy, safety or a future prescribing model.
Both BPL-003 and VLS-01 remain investigational. AtaiBeckley’s clinical-trials information page says its compounds are not approved for use. It describes an open-label BPL-003 study assessing safety, tolerability and pharmacodynamics, and a VLS-01 trial with a placebo comparator, but does not provide trial results or sample sizes. No peer-reviewed clinical-results report is part of the acquisition announcement.
That distinction limits what can be inferred from the transaction. The closing verifies Lilly’s ownership of the pipeline; it does not validate the underlying treatments. Nor does the milestone structure establish a current Phase 3 status for BPL-003. The disclosed payout condition for that program is U.S. approval and DEA rescheduling by the fifth anniversary, while the explicit Phase 3-initiation trigger applies to VLS-01.
Closing follows regulatory clearance steps
The completed merger marks the end of a process that included shareholder approval and antitrust review. An earlier AtaiBeckley SEC filing reported that the U.S. waiting period under the Hart-Scott-Rodino Act expired on Aug. 28. Lilly said AtaiBeckley shareholders had approved the transaction before the Sept. 11 close.
For Lilly, the acquisition places future decisions on development priorities, trial design and regulatory submissions under one owner. For former AtaiBeckley shareholders, the public equity has been replaced by cash and a narrowly defined claim on future milestones. The first CVR deadline arrives if a Phase 3 VLS-01 trial is initiated before Sept. 11, 2030; the later approval-and-rescheduling conditions extend to 2031 for BPL-003 and 2033 for VLS-01.
